Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apixaban Fails Phase III Knee Surgery Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Partnership with Pfizer cushions blow to Bristol-Myers’ new blood thinner.

You may also be interested in...



Bristol/Pfizer's Apixaban Bests Lovenox At Preventing VTE In Knee Surgery In Second Attempt

After failing to show non-inferiority in ADVANCE I, the Bristol/Pfizer anticoagulant was soundly superior to enoxaparin in ADVANCE II.

Bristol/Pfizer's Apixaban Bests Lovenox At Preventing VTE In Knee Surgery In Second Attempt

After failing to show non-inferiority in ADVANCE I, the Bristol/Pfizer anticoagulant was soundly superior to enoxaparin in ADVANCE II.

Bristol/Pfizer's Apixaban Bests Lovenox At Preventing VTE In Second Attempt

With the positive results of the ADVANCE II study of Bristol-Myers Squibb/Pfizer's apixaban now offsetting the failed non-inferiority of the earlier ADVANCE I study, the ADVANCE III study is shaping up to be the tie-breaker for how the investigational anticoagulant stacks up against Sanofi-Aventis' low molecular weight heparin Lovenox (enoxaparin) in patients undergoing orthopedic surgery

Related Content

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel